U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H20N6O.2ClH
Molecular Weight 421.324
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IMIDOCARB HYDROCHLORIDE

SMILES

Cl.Cl.O=C(NC1=CC=CC(=C1)C2=NCCN2)NC3=CC=CC(=C3)C4=NCCN4

InChI

InChIKey=MLRXMTYSQKIKAK-UHFFFAOYSA-N
InChI=1S/C19H20N6O.2ClH/c26-19(24-15-5-1-3-13(11-15)17-20-7-8-21-17)25-16-6-2-4-14(12-16)18-22-9-10-23-18;;/h1-6,11-12H,7-10H2,(H,20,21)(H,22,23)(H2,24,25,26);2*1H

HIDE SMILES / InChI

Molecular Formula C19H20N6O
Molecular Weight 348.4017
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Imidocarb is a carbanilide derivative with antiprotozoal activity. It is usually administered as the dipropionate salt. Imidocarb is a drug sold under the brand name Imizol and is used to treat canine ehrlichiosis. wo mechanisms of action have been proposed: As the effect of imidocarb on Trypanosoma brucei is antagonized by excess polyamines, it is has been suggested that imidocarb interferes with their production and/or use. Imidocarb blocks the entry of inositol into erythrocytes containing Babesia, resulting in starvation of the parasite. It is generally accepted in that imidocarb has anticholinesterase activity.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
590.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Imizol

Approved Use

For the treatment of babesiosis in dogs with clinical signs and/or demonstrated Babesia organisms in the blood.

Launch Date

1997
Curative
IMIDOCARB

Approved Use

For treatment of babesiosis in cattle and horses

Launch Date

2001
PubMed

PubMed

TitleDatePubMed
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.
1992 Sep
Residual effect of antibabesial drugs on the live redwater blood vaccines.
2002 Oct
Evaluation of certain veterinary drug residues in food.
2003
In-vivo therapeutic efficacy trial with artemisinin derivative, buparvaquone and imidocarb dipropionate against Babesia equi infection in donkeys.
2003 Nov
Concurrent bartonellosis and babesiosis in a dog with persistent thrombocytopenia.
2003 Nov 1
Imidocarb, a potent anti-protozoan drug, up-regulates interleukin-10 production by murine macrophages.
2003 Sep 19
[A literature review of equine piroplasmosis after an episode of acute babesiosis in a Dutch Standardbred foal after a stay in Normandy].
2005 Dec 1
Autochthonous canine babesiosis in The Netherlands.
2005 Jul 15
Identification of anti-babesial activity for four ethnoveterinary plants in vitro.
2005 Jun 10
Clinical and clinicopathological changes in 6 healthy ponies following intramuscular administration of multiple doses of imidocarb dipropionate.
2005 Mar
Effective imidocarb dipropionate therapy for Babesia shortti in falcons.
2006 Feb 18
Pharmacokinetics and mammary elimination of imidocarb in sheep and goats.
2006 Jul
Failure of imidocarb dipropionate to clear experimentally induced Ehrlichia canis infection in dogs.
2006 Jul-Aug
Flow cytometric evaluation of selected antimicrobial efficacy for clearance of Anaplasma marginale in short-term erythrocyte cultures.
2006 Jun
Effect of imidocarb and levamisole on the experimental infection of BALB/c mice by Leishmania (Leishmania) amazonensis.
2006 Jun 30
Clinicopathological changes and effect of imidocarb therapy in dogs experimentally infected with Babesia canis.
2006 Mar
Chemotherapy against babesiosis.
2006 May 31
Clinical manifestations of canine babesiosis in Hungary (63 cases).
2006 Sep
Comparison of the efficacy of enrofloxacin, imidocarb, and oxytetracycline for clearance of persistent Anaplasma marginale infections in cattle.
2006 Winter
Pharmacokinetics and bioavailability of imidocarb dipropionate in swine.
2007 Aug
Histological and ultrastructural studies of renal lesions in Babesia canis infected dogs treated with imidocarb.
2007 Dec
Molecular characterisation of Babesia gibsoni infection from a pit-bull terrier pup recently imported into South Africa.
2007 Mar
Evidence of an acute phase response in dogs naturally infected with Babesia canis.
2007 Mar 31
Therapeutic and prophylactic efficacy of imidocarb dipropionate on experimental Babesia ovis infection of lambs.
2007 Oct 21
[Dogs babesiosis--still actually problem].
2008
Canine vector-borne diseases in Brazil.
2008 Aug 8
Treatment of Mycoplasma wenyonii infection in cows with imidocarb dipropionate injection-acupuncture.
2008 Dec
Repeated high dose imidocarb dipropionate treatment did not eliminate Babesia caballi from naturally infected horses as determined by PCR-reverse line blot hybridization.
2008 Feb 14
The clinical course of babesiosis in 76 dogs infected with protozoan parasites Babesia canis canis.
2009
Diagnosis and treatment of Babesia odocoilei in captive reindeer (Rangifer tarandus tarandus) and recognition of three novel host species.
2009 Mar
Babesia and its hosts: adaptation to long-lasting interactions as a way to achieve efficient transmission.
2009 Mar-Apr
Failure of imidocarb dipropionate to eliminate Hepatozoon canis in naturally infected dogs based on parasitological and molecular evaluation methods.
2010 Aug 4
First case of babesiosis caused by Babesia canis canis in a dog from Norway.
2010 Aug 4
Patents

Sample Use Guides

In Vivo Use Guide
Use intramuscularly or subcutaneously at a rate of 6.6 mg/kg (3 mg/lb) body weight. Repeat the dose in two (2) weeks, for a total of two (2) treatments.
Route of Administration: Other
In Vitro Use Guide
The concentration of Imidocarb causing 50% inhibition of [3H]hypoxanthine incorporation (ID50 value) by Babesia bovis (Lismore and Samford isolates) cultured in vitro for Imidocarb was determined to be 3 ng/ml (8.6 nM).
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:21:23 GMT 2023
Edited
by admin
on Fri Dec 15 15:21:23 GMT 2023
Record UNII
KCC1V76AH8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IMIDOCARB HYDROCHLORIDE
MART.   USAN  
USAN  
Official Name English
IMIDOCARB HYDROCHLORIDE [USAN]
Common Name English
NSC-51189
Code English
N,N'-BIS(3-(4,5-DIHYDRO-1H-IMIDAZOL-2-YL)PHENYL)UREA DIHYDROCHLORIDE
Systematic Name English
IMIDOCARB DIHYDROCHLORIDE
MI  
Common Name English
UREA, N,N'-BIS(3-(4,5-DIHYDRO-1H-IMIDAZOL-2-YL)PHENYL)-, DIHYDROCHLORIDE
Common Name English
IMIDOCARB HYDROCHLORIDE [MART.]
Common Name English
IMIDOCARB DIHYDROCHLORIDE [MI]
Common Name English
4A65
Code English
IMIDOCARB HCL
Common Name English
3,3'-DI-2-IMIDAZOLIN-2-YLCARBANILIDE DIHYDROCHLORIDE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C277
Created by admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID30201240
Created by admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
PRIMARY
SMS_ID
300000023746
Created by admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
PRIMARY
MERCK INDEX
m6226
Created by admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
PRIMARY Merck Index
NCI_THESAURUS
C76422
Created by admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
PRIMARY
ChEMBL
CHEMBL427342
Created by admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
PRIMARY
ECHA (EC/EINECS)
226-179-7
Created by admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
PRIMARY
NSC
51189
Created by admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
PRIMARY
PUBCHEM
21388
Created by admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
PRIMARY
FDA UNII
KCC1V76AH8
Created by admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
PRIMARY
CAS
5318-76-3
Created by admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY